Furthermore, clinical trials with a humanized anti-Aβ monoclonal antibody, bapineuzumab, revealed that the treatment improved cognitive decline and retarded the brain volume loss in APOE4 non-carrier patients [12]. The gene discussed is APOE; the disease is Mental deterioration.